FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 301:1073-1076 November 15, 1979 Number 20 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In 11 hypertriglyceridemic patients on hemodialysis, clofibrate (1 to 1.50 g per week) reduced plasma triglyceride (-40 +/- 20%, P less than 0.001), very-low-density-lipoprotein triglyceride (-44 +/- 20%, P less than 0.001) and very-low-density lipoprotein cholesterol (-39 +/- 25%, P less than 0.01), and it increased high-density-lipoprotein cholesterol (82 +/- 106%, P less than 0.005). Low pretreatment lipoprotein-lipase activity in adipose-tissue specimens and postheparin plasma increased to normal with clofibrate, whereas low hepatic triglyceride lipase activity did not change. The reduced very-low-density-lipoprotein triglyceride correlated with the increased lipoprotein-lipase activity in adipose tissue (rs = 0.792, P less than 0.02, n = 8) and postheparin plasma (rs = 0.851, P less than 0.02, n = 8), whereas increased high-density-lipoprotein cholesterol correlated with changes in this activity in adipose tissue (rs = 0.696, P less than 0.06) and post-heparin plasma (rs = 0.679, P less than 0.10). There was no correlation between changes in hepatic triglyceride lipase activity and plasma lipids during treatment. Reduced lipoprotein-lipase activity may cause hypertriglyceridemia and decreased high-density-lipoprotein cholesterol in patients on hemodialysis; clofibrate may correct these abnormalities by increasing lipoprotein-lipase activity to normal.

This article has been cited by other articles:

• de Boer, I. H., Astor, B. C., Kramer, H., Palmas, W., Seliger, S. L., Shlipak, M. G., Siscovick, D. S., Tsai, M. Y., Kestenbaum, B. (2008). Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis. CJASN 3: 125-132 [Abstract] [Full Text]  
• ANDO, M., SANAKA, T., NIHEI, H. (1999). Eicosapentanoic Acid Reduces Plasma Levels of Remnant Lipoproteins and Prevents in Vivo Peroxidation of LDL in Dialysis Patients. J. Am. Soc. Nephrol. 10: 2177-2184 [Abstract] [Full Text]  
• Vaziri, N. D., Wang, X. Q., Liang, K. (1997). Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am. J. Physiol. Renal Physiol. 273: F925-F930 [Abstract] [Full Text]  
• Ribalta, J., LaVille, A. E., Girona, J., Vallve, J. C., Masana, L. (1997). Low plasma vitamin A concentrations in familial combined hyperlipidemia. Clin. Chem. 43: 2379-2383 [Abstract] [Full Text]  
• and Jacob Bar-Tana, R. H. J. B.-S., Hertz, R. (1995). Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. J. Biol. Chem. 270: 13470-13475 [Abstract] [Full Text]  
• Staels, B, Auwerx, J (1992). Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Development 115: 1035-1043 [Abstract]